The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.

Radiopharmaceutical specialist Lantheus Holdings (NASDAQ: LNTH) had some news to report Tuesday morning, but the market ...

Lantheus Holdings, Inc. (NASDAQ:LNTH) agreed to acquire Evergreen Theragnostics, Inc. in an all-cash transaction involving an ...

Lantheus Holdings Inc. is adding to its portfolio yet again, acquiring a clinical-stage radiopharmaceutical company in a deal ...

Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...

Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LNTH stock, giving a Buy rating yesterday.Invest with Confidence: ...

On a quest to carve out a spot as one of the nuclear medicine greats, Massachusetts-based radiopharmaceutical specialist ...

Lantheus (LNTH) announced the appointment of Phuong Khanh Morrow, M.D. to Lantheus’ Board of Directors, effective February 1, 2025. As an ...

Lantheus Holdings is stepping up its game in the radiopharmaceutical space by acquiring Massachusetts-based Evergreen ...

Lantheus ( ($LNTH) ) has shared an update. On January 27, 2025, Lantheus Medical Imaging, a subsidiary of Lantheus Holdings, announced an ...

Lantheus Holdings Inc., a radiopharmaceutical-focused company, has agreed to acquire Evergreen Theragnostics Inc., in an ...

Massachusetts-based radiopharmaceutical company Lantheus (Nasdaq: LNTH) has announced a plan to acquire clinical-stage ...